ArticleParasites & vectors2022
Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni.
Article in Parasites & vectors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic, prognostic, and therapeutic potentials of gut microbiome profiling in human schistosomiasis: A comprehensive systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Behaviour change interventions for the control and elimination of schistosomiasis: A systematic review of evidence from low- and middle-income countries.PLoS neglected tropical diseases · 2023Pooled it
- Effect of behavioral interventions on schistosomiasis-related knowledge, attitudes, and practices of schoolchildren in Pemba, Tanzania: A 4-year repeated cross-sectional study.PLoS neglected tropical diseases · 2025Trial
- Epidemiology and Current Challenges of Human Schistosomiasis Along the Shabelle River, Somali Regional State, Eastern Ethiopia.Acta parasitologica · 2025Article
- Identifying hotspots of S. haematobium infection following praziquantel treatment during multiple annual mass drug administration campaigns in Zimbabwe.PLoS neglected tropical diseases · 2025Article
- Introduction of epigenetic variation contribute to resistance against the human parasite Schistosoma mansoni.Epigenetics & chromatin · 2025Article
- How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis.PLoS neglected tropical diseases · 2025Article
- Revisiting immunity vs. exposure in schistosomiasis: A mathematical modeling study of delayed concomitant immunity.PNAS nexus · 2024Article
- Urogenital schistosomiasis in schoolchildren in the lake zones of Kankossa and Oued Rawdha, southern Mauritania: The first parasitological and malacological survey.PLoS neglected tropical diseases · 2024Article
- Parasites of the liver: A global problem?World journal of gastroenterology · 2024Article
- Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis.Animal microbiome · 2024Article
- Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis.European journal of microbiology & immunology · 2024Review
- Beyond schistosomiasis: unraveling co-infections and altered immunity.Clinical microbiology reviews · 2024Review
- Article
- Human Schistosomiasis Vaccines as Next Generation Control Tools.Tropical medicine and infectious disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn January 2021, the World Health Organization published the 2021-2030 roadmap for the control of neglected tropical diseases (NTDs). The goal for schistosomiasis is to achieve elimination as a public health problem (EPHP) and elimination of transmission (EOT) in 78 and 25 countries (by 2030), respectively. Mass drug administration (MDA) of praziquantel continues to be the main strategy for control and elimination. However, as there is limited availability of praziquantel, it is important to determine what volume of treatments are required, who should be targeted and how frequently treatment must be administered to eliminate either transmission or morbidity caused by infection in different endemic settings with varied transmission intensities. METHODS AND
resultsIn this paper, we employ two individual-based stochastic models of schistosomiasis transmission developed independently by the Imperial College London (ICL) and University of Oxford (SCHISTOX) to determine the optimal treatment strategies to achieve EOT. We find that treating school-age children (SAC) only is not sufficient to achieve EOT within a feasible time frame, regardless of the transmission setting and observed age-intensity of infection profile. Both models show that community-wide treatment is necessary to interrupt transmission in all endemic settings with low, medium and high pristine transmission intensities.
conclusionsThe required MDA coverage level to achieve either transmission or morbidity elimination depends on the prevalence prior to the start of treatment and the burden of infection in adults. The higher the worm burden in adults, the higher the coverage levels required for this age category through community-wide treatment programmes. Therefore, it is important that intensity and prevalence data are collected in each age category, particularly from SAC and adults, so that the correct coverage level can be calculated and administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.